FDA Drug Safety Communication: Modified dosing recommendations to improve the safe use of Erythropoiesis-Stimulating Agents (ESAs) in chronic kidney d

[FDA]

[6-23-2011] The U.S. Food and Drug Administration (FDA) is informing healthcare professionals that new recommendations for more conservative dosing of Erythropoiesis-Stimulating Agents (ESAs) in patients with chronic kidney disease (CKD) have been approved to improve the safe use of these drugs.


Baca selengkapnya di : http://www.fda.gov...